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a b s t r a c t
Previous in vitro studies have demonstrated that Ebola and Marburg virus (EBOV and MARV) VP35
antagonize the host cell immune response. Moreover, speciﬁc mutations in the IFN inhibitory domain (IID)
of EBOV and MARV VP35 that abrogate their interaction with virus-derived dsRNA, lack the ability to inhibit
the host immune response. To investigate the role of MARV VP35 in the context of infectious virus, we used
our reverse genetics system to generate two recombinant MARVs carrying speciﬁc mutations in the IID region
of VP35. Our data show that wild-type and mutant viruses grow to similar titers in interferon deﬁcient cells,
but exhibit attenuated growth in interferon-competent cells. Furthermore, in contrast to wild-type virus, both
MARV mutants were unable to inhibit expression of various antiviral genes. The MARV VP35 mutants exhibit
similar phenotypes to those previously described for EBOV, suggesting the existence of a shared immune-
modulatory strategy between ﬁloviruses.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Filoviruses (order Mononegavirales) are enveloped viruses with
a single-strand RNA genome of negative-sense polarity (Feldmann
et al., 2013). The viral genome is approximately 19 kb and encodes
7 genes: NP, VP35, VP40, GP, VP30, VP24, and L. These genes are
separated by 6 intragenic untranslated regions and transcribed in
sequential order from the 30 to the 50 end of the viral genome
(Fig. 1A). Several viruses of the Filoviridae family, such as Ebola
(EBOV), Sudan, Bundibugyo, Marburg (MARV), and Ravn viruses,
cause sporadic outbreaks of viral hemorrhagic fevers (VHFs) in
sub-Saharan Africa with high case fatality rates (Albarino et al.,
2013a; Hartman et al., 2010; Leroy et al., 2011). Three other
ﬁloviruses, Tai Forest virus, Reston virus, and Lloviu virus, have
not caused known human fatalities to date (Feldmann et al., 2013;
Leroy et al., 2011; Negredo et al., 2011).
A critical component of ﬁlovirus replication is the ability of
virus-encoded proteins, such as the well-studied VP35 protein, to
modulate the host immune response [see review in (Ramanan
et al., 2011) and Fig. 1B]. The VP35 protein from EBOV and MARV,
has been shown in protein expression studies to inhibit production
of IFNβ by binding to dsRNA through a central basic patch (CBP) in
the IFN inhibitory domains (IID), and block recognition of patho-
gen associated molecular patterns (PAMPs) by retinoic-acid indu-
cible gene I (RIG-I)-like receptor (RLR) pathways (Bale et al., 2012;
Bale et al., 2013; Leung et al., 2009; Leung et al., 2010; Ramanan
et al., 2011; Zinzula et al., 2012). EBOV VP35 also inhibits the
induction of RIG-I by PACT (Luthra et al., 2013) and dampens RIG-I
signaling by interacting with the TBK-1/IKKε kinase and inhibiting
IRF-3/7 phosphorylation (Cardenas et al., 2006; Hartman et al.,
2006; Hartman et al., 2004; Prins et al., 2009). Moreover, EBOV
VP35 was also shown to inhibit RNA silencing by interacting with
two dsRNA-binding proteins, TRBP and PACT (Fabozzi et al., 2011;
Zhu et al., 2012). In accordance with these ﬁndings, recombinant
EBOV carrying speciﬁc mutations in the CBP region of VP35 showed
an attenuated phenotype in mice and guinea pigs (Hartman et al.,
2008; Prins et al., 2010a). In addition other ﬁlovirus proteins, such
as VP24 and sGP from EBOV, and VP40 fromMARV and Reston virus
(Fig.1B) inhibit the host immune response by different mechanisms
(Basler et al., 2004; Mateo et al., 2011; Mateo et al., 2010; Mohan
et al., 2012; Reid et al., 2006; Reid et al., 2007; Valmas and Basler,
2011; Valmas et al., 2010).
In this report, we investigated the immune modulatory func-
tion of VP35 in MARV replication by engineering speciﬁc lesions
designed to abrogate dsRNA PAMP recognition, and measure the
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effects of these mutations in the context of infectious virus. The
mutant MARVs were generated using a recently developed reverse
genetics system (Albarino et al., 2013b) derived from a MARV bat
isolate and their phenotype and characterized in interferon-
competent cells.
Results and discussion
To characterize relative MARV VP35 immune modulatory activ-
ities in our system, we compared the abilities of EBOV VP35 and
MARV VP35, VP24, and VP40 to inhibit IFNβ production induced by
Sendai virus (SeV). For this purpose, HEK-293 T cells were co-
transfected with Pol lI expression plasmids encoding each of the
viral proteins (EBOV-VP35, MARV-VP35, MARV-VP24, or MARV-
VP40), an IFNβ promoter-driven ﬁreﬂy luciferase (FLuc) reporter
plasmid, and a Renilla luciferase (RLuc) transfection control plasmid.
24 h post-transfection (hpt), cells were induced by SeV infection,
and luciferase activity was measured one day post infection (dpi). As
shown in Fig. 1C, MARV VP35 inhibits IFNβ promoter activity to a
greater extent than either MARV VP24 or VP40, while EBOV VP35
showed the most robust effect, as previously reported (Bale et al.,
2012). Our results with MARV VP40 on the IFNβ promoter are
consistent with those previously described for this protein (Valmas
and Basler, 2011; Valmas et al., 2010) while the effect of MARV VP24
is consistent with the well characterized role of EBOV VP24 as an IFN
antagonist (Mateo et al., 2011; Mateo et al., 2010; Reid et al., 2006;
Reid et al., 2007). Although a direct role as IFN antagonist has not
been reported for MARV VP24, two recent reports describe an
association of this protein with the interference of the inﬂammatory
response (Edwards et al., 2014; Page et al., 2014).As shown in Fig. 2A
and by others (Bale et al., 2012; Hartman et al., 2004; Prins et al.,
2010b; Ramanan et al., 2012), the IFN inhibitory domain (IID) located
in the C-terminal region of VP35 is strongly conserved among
ﬁloviruses. Previous reports showed that mutations in R312 of EBOV
VP35, and in the equivalent position of MARV VP35 (R301), abrogate
RNA binding and IFN suppression. In contrast, mutations in R305 of
EBOV VP35 or R294 in MARV VP35 only moderately suppress these
abilities (Bale et al., 2012; Bale et al., 2013; Hartman et al., 2006;
Hartman et al., 2004; Leung et al., 2009; Leung et al., 2010; Ramanan
et al., 2012). Moreover, recombinant EBOV with mutations in R305
and R312 of VP35 exhibited different in vitro and in vivo phenotypes
when compared to WT virus (Hartman et al., 2008; Hartman et al.,
2006).
In order to further characterize the immune modulatory
activity of MARV VP35, we introduced two speciﬁc aminoacids
changes, R294A and R301A, into the WT expression plasmid, and
tested the activity of the IFNβ promoter-driven FLuc as described
above. As shown in Fig. 2B, WT MARV VP35 exhibits the most
robust inhibition of IFNβ promoter activity. Both mutated forms of
VP35 were less effective, particularly R301A. To conﬁrm that the
observed phenotypes were due to the introduced mutations and
not differences in expression levels, we used Western blot analysis
to quantitate the amounts of WT and mutated forms of VP35
produced in transfected cells. When compared to actin levels,
there are no substantial changes in R294A and R301A protein
Fig. 1. (A) Basic organization of the MARV genome. The 7 ORFs are depicted in the viral complementary sense (50 to 30). (B) Filovirus proteins involved in immune evasion.
The immune modulator functions of ﬁlovirus proteins are divided into three broad classes; citations are included. (C) IFNβ promoter assay in SeV infected cells. HEK-293 cells
were co-transfected with expression plasmids encoding EBOV VP35, MARV VP35, MARV VP24, or MARV VP40, along with p125-luc reporter plasmid expressing ﬁreﬂy
luciferase (FLuc), and pRL-TK control plasmid expressing Renilla luciferase (RLuc). Cells were infected with SeV 24 hpt, and luciferase activity was measured 1 dpi. FLuc
activity was normalized to RLuc, and the fold-increase in induction was determined by comparing infected cells with uninfected cells.
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Fig. 2. (A) Sequence conservation in central basic patch (CBP) of ﬁlovirus VP35 IFN-inhibiting domain (IID). Partial amino acid sequences were aligned to show the
conservation of IID. The two amino acid residues modiﬁed in EBOV in a previous report (Hartman et al. 2006), and in MARV in this current report are indicated with arrows.
VP35 sequences were derived from accession numbers AF086833, NC_004161, FJ217162, NC_014373, NC_006432, DQ447649, NC_001608, and FJ750958. (B) IFNβ promoter
assay. HEK-293 cells were co-transfected with expression plasmids encoding WT MARV VP35, or the mutant proteins VP35-294 or VP35-301, Cells were infected with SeV 24
hpt, and luciferase activity was measured as described in Fig.1C. (C) Expression of WT and mutant VP35. HEK-293 cells were transfected as described above, and protein
lysates were immunostained with antibodies against MARV (upper panel) or actin (lower panel). (D) Minigenome replication. Schematic of MARV Luc minigenome system.
The structure of plasmids coding the minigenome (Uebelhoer et al., 2014) is shown with 371Bat 5’ and 3’ untranslated regions (black line), and support plasmids expressing
viral proteins (dashed line indicates pCAGGS plasmid sequence). Amino acid substitutions to alanine in VP35 are indicated for pC-VP35-294 and pC-VP35-301 expression
plasmids. To assess minigenome replication BSR-T7/5 cells co-transfected with plasmids encoding the MARV mini-genome and with support plasmids expressing viral
proteins pC-NP, pC-VP35, pC-VP30, and pC-L. In the indicated lanes, pCVP35 was swapped for pC-VP35-294, pC-VP35-301, or pC-L was swapped for pCAGGS as a no
polymerase control. Data are representative of three independent experiments, with mean and standard error of the mean (SEM) of luciferase expression from three wells
displayed for each time point in relative light units (RLUs). (B).
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expression levels that could be linked to the decreased ability to
inhibit the IFNβ promoter (Fig. 2C).
Based on the pronounced inhibitory effect of MARV VP35 on IFNβ
production in human 293 T cells compared to the other MARV
proteins (Fig. 1C), we wanted to further characterize the role of
VP35 in dampening host cell PAMP recognition in the context of
MARV infection. Before attempting the rescue of VP35 mutant MARV,
we wanted to conﬁrm that R294A and R301A mutations in VP35
would had deleterious effects on the MARV minigenome system.
To do so, WT and mutant MARV VP35 expression plasmids were
co-transfected with MARV NP, VP30, and L plasmids, along with the
MARV minigenome expressing Gaussia Luciferase (gLuc) (Uebelhoer
et al., 2014). Consistent with previous reports for EBOV VP35
(Hartman et al., 2006), the MARV VP35 mutations had no deleterious
effects on the minigenome activity (Fig. 2D).
Using the MARV reverse genetics system (Albarino et al., 2013b;
Uebelhoer et al., 2014), we generated WT recombinant MARV
(rMARV) and two mutant viruses, rMARV-294 and rMARV-301,
carrying R294A or R301A amino acid changes in VP35 respectively
(Fig. 3A). Co-transfection of transcription plasmids containing
the full-length genomes and support plasmids allowed the rescue
of recombinant viruses in BHK cells. Viral stocks were further
propagated by two passages in Vero-E6 cells, and growth kinetics
were examined in Vero-E6 cells. As shown in Fig. 3B, rMARV, rMARV-
294, and rMARV-301 all exhibited similar growth kinetics in Vero-E6
cells, supporting our minigenome ﬁndings that, similar to EBOV,
these mutations do not deleteriously affect the function of VP35 in
MARV RNA replication.
To examine the immune modulatory role of VP35, we used
rMARV, rMARV-294, and rMARV-301 to infect HEK-293 T cells stably
transfected with an IFNβ promoter-driven FLuc reporter plasmid
(293 T-IFNβ-FF). Infected cells were lysed 3 dpi, and luciferase
activity was measured. Mock and rMARV-infected cells showed
comparable levels of luciferase activity in (Fig. 3C). In contrast, cells
infected with rMARV-294 showed slightly higher IFNβ promoter-
driven FLuc activity, while those infected with rMARV-301 showed
the highest relative FLuc activity. These results suggest that rMARV-
294 and rMARV-301 viruses differ in their ability to modulate IFNβ
activity.
We next compared the growth kinetics of WT and mutant rMARV
in three different immuno-competent cell lines: Huh7 and A549
human-derived cell lines, and CD14þ macrophages, a primary target
of viral replication during the course of primate infections. As shown
in Fig. 4A, WT and mutant viruses exhibited similar growth kinetics
in Huh7. In contrast, WT rMARV had a slight growth advantage over
the mutant viruses in A549 cells and a 1–2 log advantage in CD14þ
Fig. 3. Rescue and characterization of recombinant WT and mutant MARV viruses. (A) Schematic representation of recombinant MARV genomes. Full-length MARV
complementary genome is depicted with the amino acid substitutions in VP35 indicated for rMARV-294 and rMARV-301 mutants viruses. WT and mutant recombinant
viruses were rescued in BHK-21 cells and passaged twice in Vero-E6 cells as described before (Albarino et al., 2013b). (B) Growth kinetics in Vero-E6 cells. Cells were infected
with rMARV, rMARV-294, or rMARV-301 mutants viruses (moi¼0.02). After 1 h adsorption followed by three PBS washes, supernatants were collected at the indicated time
points. Viral titers were measured by tissue culture infective dose 50 (TCID50) in Vero-E6 cells as described before (Uebelhoer et al. 2014). (C) IFN-β promoter assay in MARV
infected cells. HEK-293 cells stably transfected with an IFN-β promoter-driven FLuc reporter plasmid (293 T-IFNβ-FF) were infected with rMARV, rMARV-294, or rMARV-301.
Cells were lysed 3 dpi, and luciferase activity was measured.
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human macrophages. The different phenotypes of these recombinant
viruses are consistent with previous reports of EBOV carrying the
equivalent mutations in VP35 when tested in immune-competent
cells, such as human macrophages (Hartman et al., 2006).
We suspect that the reduced growth of mutant viruses in CD14þ
macrophages is due to their impaired ability to control the innate
antiviral response during the course of infection. In order to test this
hypothesis, we infected CD14þ macrophages with WT and mutant
viruses and analyzed the expression of selected genes involved in
the innate antiviral response. As shown in Fig. 4B, nearly all of the
antiviral genes tested were over-expressed in macrophages infected
by the mutants compared to those infected by WT virus. Infection by
MARV-301 caused the greatest induction of innate immune genes
and was also the mutant that was the most attenuated in CD14þ
macrophages, thereby linking attenuated growth to the inability to
antagonize innate immune responses. Consistent with this hypoth-
esis, we found Huh7 and A549 cells to exhibit very minor changes in
the expression level of these same antiviral genes (data not shown),
when infected with wild-type or mutant viruses.
Conclusions
In this report we describe the successful generation of bat-
derived recombinant MARV carrying mutations in VP35. Using
these mutant MARVs, we demonstrated the ability of MARV VP35
to modulate expression of host immune response genes during
infection of immune-competent cells. These mutant viruses lack
the ability to suppress the innate antiviral response, resulting in
high expression levels of several critical antiviral genes that
correlate with impaired growth in human macrophages. Based
on comparison to the growth phenotypes of analogous EBOV VP35
mutants with defects in dsRNA PAMP recognition (Hartman et al.,
2006), these data suggest shared immune-modulatory strategies
between genera within the family Filoviridae. It should be noted
that MARV VP35, VP40, and VP24 likely function together as
immune modulators. Indeed, the role of VP40 has been well
characterized for MARV (Valmas and Basler, 2011; Valmas et al.,
2010), while the role of VP24 as an IFN antagonist has been only
reported for EBOV (Edwards et al., 2014; Mateo et al., 2011; Mateo
et al., 2010; Page et al., 2014; Reid et al., 2006; Reid et al., 2007),
and will warrant further investigation.
Materials and methods
Cell culture and biosafety
All work with WT or recombinant MARV was performed in a
biosafety level 4 (BSL-4) facility. BSR-T7/5, BHK21, and Vero-E6
Fig. 4. A. Growth kinetics of WT and VP35 mutants in IFN-competent cells. Huh7, A549 and human macrophages were infected with WT rMARV, rMARV-294, or rMARV-301,
and viral titers were determined by TCID50 assay in Vero-E6 cells. Substantial changes in growth kinetics were noticed only in CD14þ macrophages. B. Expression of antiviral
genes in cells infected with WT or mutant MARV. Selected genes corresponding to four groups associated with different receptors and their signaling pathways (type-I IFN,
Nod-like receptor, toll-like receptor, and RIG-I-like receptor) with important fold regulation values (cut-off¼10) are shown.
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cells were propagated in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 5% fetal bovine serum (FBS) and
penicillin-streptomycin (Pen-Strep), as recommended by the man-
ufacturer (Invitrogen). BSR-T7/5 cells were a generous gift from
K. Conzelmann (Buchholz et al., 1999). CD14þ macrophages were
puriﬁed and seeded as previously described (Albarino et al.,
2013b; McElroy and Nichol, 2012)
Plasmid construction
The construction of support plasmids, gLuc minigenome, and
full-length clones corresponding to the full-length genome of
371Bat MARV (GenBank FJ750958) has been described before
(Albarino et al., 2013b; Uebelhoer et al., 2014). Complete details
on the construction of support expression plasmids and plasmids
encoding a full-length clone carrying mutations in the C-terminal
region of VP35 are available upon request. Brieﬂy, the CGC codon
at position 3,824 and the CGG codon at position 3,845 were
changed to GCA in order to introduce the R294A and R301A amino
acid changes in the VP35 protein.
Minigenome expression
A 75% conﬂuent monolayer of BSR-T7/5 cells grown in 12-well
plates was transfected with 1.5 μg of MARV gLuc minigenome
plasmid, 0.5 μg pC-L, 0.5 μg pC-NP, 0.05 μg pC-VP30, and 0.05 μg
pC-VP35 WT or mutant plasmids. Plasmid pC-L was replaced by
empty pCAGGS in the control. Aliquots of 5–10 μL of supernatant
were collected 2–4 days post-transfection (dpt) to measure gLuc
activity, as described before (Uebelhoer et al., 2014).
Rescue of infectious viruses
Rescue of recombinant viruses was performed in BHK21 cells as
described previously (Albarino et al., 2013b). Brieﬂy, a 70% conﬂuent
monolayer of BHK21 cells grown in 12-well plates was transfected
with 1.5 μg pMARV (expressing the full-length MARV genome in viral-
complementary sense), 0.5 μg pC-L, 0.5 μg pC-NP, 0.05 μg pC-VP35,
0.05 μg pC-VP30, and 0.5 μg of pC-T7. Supernatants from the trans-
fected cells were harvested 4 dpt, clariﬁed by low-speed centrifuga-
tion, and passaged twice in Vero-E6 cells. The rescued viruses were
sequenced to completion and no unexpected changes were noted. The
complete sequence of recombinant wild-type and mutant viruses
were deposited in GenBank (KP117261, KP117260, KP117259).
Virus titration and growth curves
To characterize the growth kinetics of recombinant viruses,
2106 Huh7 and A549 cells, or 1105 CD14þ macrophages were
infected with WT or mutant viruses at multiplicity of infection
(moi) of 0.02. Virus was allowed to adsorb for 1 h with gentle
rocking. After adsorption, monolayers were washed three times
with PBS to eliminate any residual virus. Aliquots of 200 μL of the
supernatant were taken daily, and viral titers were obtained by a
tissue culture infective dose 50 (TCID50) assay, as described before
(Uebelhoer et al., 2014).
IFNβ promoter assay in SeV infected cells
Subconﬂuent monolayers of HEK-293 cells were co-transfected
with pCAGGS plasmids encoding various viral proteins, the p125-luc
FLuc reporter plasmid, and a plasmid constitutively expressing the
RLuc (pRL-TK). The IFNβ FLuc reporter plasmid p125-luc, kindly
provided by T. Fujita (Tokyo Metropolitan Institute of Medical
Science, Tokyo, Japan), expresses FLuc under the control of the
murine IFN-β promoter region (Yoneyama et al., 1996). The pRL-TK
plasmid (Promega) contains a Herpes simplex virus thymidine kinase
(HSV TK) promoter-driven encoding RLuc, used to control for trans-
fection efﬁciency. 24 hpt, cells were induced with 200 hemagglutinin
(HA) units/mL of SeV. Infected cells were lysed 1 dpi, and luciferase
activity was measured using the Dual-Luciferase reporter assay
system according to the manufacturer's instructions (Promega). FLuc
activity was normalized to the RLuc value for each individual sample,
and the fold-induction values were obtained by comparing infected
cells with uninfected cells. Experiments were done in triplicate, and
values are expressed as percent (%) activity relative to empty vector
control set at 100% induction7SD.
IFNβ promoter assay in MARV-infected cells
293 T-IFNβ-FF cells (Baum and Garcia-Sastre, 2011), a kind gift
from Adolfo García-Sastre (Icahn School of Medicine at Mount Sinai
Hospital), were cultured in DMEM supplemented with 10% FBS, 1%
L-glutamine, and 1% Pen-Strep. Cells were plated in low-serummedia
(2% FBS) to sub-conﬂuent levels in 48-well plates, and infected with
rMARV, rMARV-294, and rMARV-301 (moi¼0.5). At 3 dpi, cells were
lysed, and luciferase activity was measured using the LARII reagent
component of the Dual-Luciferase reporter assay system, according to
the manufacturer's instructions (Promega). Activity is expressed as
average relative luciferase units (RLU) of 8 replicates7SD.
Gene expression array
Sub-conﬂuent monolayers of Huh7, A549 cells, or CD14þ selected
human macrophages grown in 24-well plates were mock-infected
or infected with rMARV, rMARV-294, or rMARV-301 (moi¼2) in
duplicate. 24 hpi, supernatants were removed, and cells were lysed
for total RNA puriﬁcation following previously described protocols
(McMullan et al., 2012). 2 μg of total RNA was subjected to an
extensive DNAse digestion following the manufacturer's protocol
(RNeasy, Qiagen), and subsequently used in a qRT-PCR reaction using
SuperScript III Platinum SYBR Green One-Step qRT-PCR and following
the manufacturer's protocol (Invitrogen). Gene expression proﬁles
were obtained using a commercially available array (Antiviral Res-
ponse PCR Array, Qiagen/SABiosciences).
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